Name
Celcuity
Company Description
We are a clinical stage biotechnology company developing targeted therapies for the treatment of multiple solid tumor indications.
The company was founded to develop a better way to treat the cellular drivers of tumor growth.
Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor.
Gedatolisib clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings.
The company was founded to develop a better way to treat the cellular drivers of tumor growth.
Our lead therapeutic candidate, gedatolisib, is an intravenously administered, potential first-in-class PI3K/AKT/mTOR (PAM) pathway inhibitor.
Gedatolisib clinical development programs are focused on the treatment of patients with HR+/HER2- ABC in the 1L and 2L settings.
Website
Product Categories (7)
Breast Cancer, Genitourinary Cancer, Gynecologic Cancer, Biotechnology, Clinical Trials, Pharmaceutical
Featured Exhibitor
Yes
Address
Minneapolis, MN
United States
United States
Badges
